Innova's PR indicates to me that the QMCH is only
Post# of 22456
The Biolab acquisition adds fast-turnaround for PCR at many locations. Evidently there is a need for PCR to confirm antigen tests under some conditions and this brings that capability in-house, giving Innova a full testing package to offer and control over the PCR testing so it can be uniformity entered into the QMCH reporting system.
Lastly it brings R&D in-house and in the USA which may affect approvals, response time, development, etc., as well as developing tests.